Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported a sale of 12,728 shares of Common Stock on May 18, 2026 at a weighted average price of $5.12 per share. According to the disclosure, these shares were sold to cover her tax liability arising from recently vested restricted stock units.
After this tax-related sale, Bauerlein directly holds 688,893 shares, which includes 169,810 shares of Common Stock and 519,083 shares that are scheduled to be issued as her remaining RSUs vest and settle over time.
SGHT filed a Form 144 notice reporting proposed sales of Common Stock by an affiliate under Rule 144. The filing lists 12,728 shares described as vested restricted stock to be sold on 05/15/2026 and discloses prior sales of 25,874 shares on 04/02/2026.
The filing shows dollar amounts tied to transactions ($65,129.18 and $90,007.90) and identifies Fidelity Brokerage Services LLC as the broker. The notice is a regulatory filing of intended and recent sales; cash‑flow recipients and timing beyond the listed dates are not detailed here.
Sight Sciences, Inc. reported first-quarter 2026 revenue of $19.7 million, up 12.5% from $17.5 million a year earlier, driven by growth in both glaucoma and dry eye products. Net loss narrowed to $13.0 million from $14.2 million as higher gross profit offset increased legal costs.
Interventional Glaucoma revenue rose to $18.3 million, while Interventional Dry Eye revenue increased to $1.4 million after new reimbursement support. Gross margin held at 86.2%. The company ended the quarter with $85.0 million in cash and cash equivalents and $40.0 million of term loan principal outstanding.
A Delaware federal court’s final judgment in the Alcon litigation awarded $55.4 million in damages and a 10% ongoing royalty on Hydrus revenue, and triggered a $5.4 million litigation success fee, while related patent reexaminations at the USPTO continue.
Sight Sciences reported first quarter 2026 revenue of $19.7 million, up 13% from a year earlier, driven by glaucoma and dry eye products. Interventional Glaucoma revenue rose to $18.3 million, while Interventional Dry Eye reached $1.4 million, a 244% year-over-year increase.
The company delivered an overall gross margin of 86% and cut quarterly cash usage to $7.0 million, ending March 31, 2026 with $85.0 million in cash and cash equivalents. Net loss narrowed to $13.0 million, or $0.24 per share.
Sight Sciences raised its full-year 2026 revenue outlook to $83.0–$89.0 million, including $77.0–$81.0 million from Interventional Glaucoma and $6.0–$8.0 million from Interventional Dry Eye. A Delaware court’s final judgment in its litigation with Alcon awarded $55.4 million in past damages and a 10% ongoing Hydrus Microstent royalty, subject to appeal.
Sight Sciences, Inc. announced that a U.S. District Court entered a Final Judgment in its patent case against Alcon, awarding the company $55.4 million in total monetary damages and confirming that the asserted patent claims are valid and were willfully infringed.
The award includes $34.0 million in past damages through April 26, 2024, $14.7 million in supplemental damages through March 31, 2026, and $6.8 million in pre‑judgment and post‑judgment interest through April 17, 2026. The judgment also grants an ongoing 10% royalty on Hydrus Microstent revenue until the last of the patents expires. However, Alcon may appeal, and Sight Sciences will not receive any monetary damages unless appeals conclude or the appeal period ends without appeal, and certain patent reexamination outcomes could affect its ability to collect.
Sight Sciences, Inc. is holding a completely virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Pacific Time to elect two Class II directors and seek ratification of Deloitte & Touche LLP as independent auditor.
Stockholders of record as of April 8, 2026, when 54,403,542 shares of common stock were outstanding and entitled to vote, may attend and vote online using a 16-digit control number. The proxy statement also details board composition, committee structures, executive officer biographies, and the company’s executive compensation philosophy.
Deloitte & Touche LLP, which has audited the company since 2019, billed audit-related fees totaling $1,461,395 for 2025. The Audit Committee recommends including the 2025 audited financial statements in the Form 10‑K and asks stockholders to ratify Deloitte’s continued engagement for 2026.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported an open-market sale of 7,231 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. According to the disclosure, the shares were sold to cover his tax liability tied to recently vesting restricted stock units.
Following this tax-related sale, Rodberg directly holds a total of 230,939 shares of common stock, including 47,160 currently held shares and 183,779 additional shares that will be acquired upon future vesting and settlement of restricted stock units. The transaction represents a small portion of his overall equity position.
Sight Sciences, Inc. Chief Legal Officer Jeremy B. Hayden sold 13,761 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this tax-related sale, he held a total of 369,770 shares, including 87,274 shares of common stock and 282,496 additional shares that will be received upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Schedule 13G/A amendment shows KCK Ltd. and Nael Karim Kassar beneficially own 1,438,094 shares of Common Stock, representing 2.7% of the class based on 54,005,984 shares outstanding as of February 26, 2026. The filing reports shared voting and dispositive power over these shares and is signed by the filer and Sight Sciences' CEO.
SGHT submitted a Form 144 disclosing proposed sales of Common Stock, including a block associated with Restricted Stock Vesting dated 03/31/2026. The filing also lists prior sales by James Rodberg of 594 shares on 01/06/2026 and 2,616 shares on 01/16/2026.